ArticleJournal of endocrinological investigation2026
Changes in cardiometabolic risk factors in transmasculine individuals over 10 years of Gender-Affirming Hormone Therapy.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeto describe 10-year changes in health measures and cardiovascular risk among transmasculine adults on testosterone-based Gender-Affirming Hormone Therapy.
methodsthis is a single-centre, longitudinal cohort study of transmasculine adults who began Gender-Affirming Hormone Therapy and were followed-up for a total of 10 years according to standard clinical practice, which includes yearly visits with complete physical examinations, blood tests, and assessment of body composition. For participants aged 35 years or older, we estimated the 10-year cardiovascular risk, and then compared it with age-matched people from the general population.
results57 participants completed 10 years of follow-up. Nearly half smoked and few were physically active. Haemoglobin and haematocrit rose early and then stabilised within usual ranges; very high values were uncommon. Fasting glucose, insulin, and blood pressure did not change meaningfully. The lipid profile worsened: LDL, total cholesterol and triglycerides increased, and HDL decreased throughout the study period. Weight, body mass index, waist circumference, and waist-to-hip ratio increased. Body composition showed higher lean mass and trunk fat, with a shift toward android fat distribution. No major cardiovascular events were recorded. One participant developed atrial fibrillation. Metabolic syndrome by female criteria became more frequent. cardiovascular risk was higher than cisgender women but similar to cisgender men at ages 35-44; at ages 45-54 it was lower than cisgender men.
conclusionsOver 10 years, testosterone-based Gender-Affirming Hormone Therapy is linked to less favorable lipid profiles and body composition patterns, supporting constant monitoring, risk-factor treatment, and lifestyle support.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.